New stomach drug may improve blood thinner safety after heart stent

NCT ID NCT07471867

Recruiting now Disease control Sponsor: Yonsei University Source: ClinicalTrials.gov ↗

First seen Apr 07, 2026 · Last updated May 21, 2026 · Updated 6 times

Summary

This study looks at whether a new acid-reducing medicine called zastaprazan works better than standard drugs (PPIs) at keeping blood thinners working properly in heart patients. About 100 adults with chronic heart disease who recently had a stent placed will take either zastaprazan or a PPI along with their blood thinners. The goal is to see if zastaprazan causes less interference with the blood thinner clopidogrel, which could lower the risk of heart attacks or clots.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC CORONARY SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Yongin Severance Hospital, Yonsei University
RECRUITING

Yongin-si, Gyeonggi-do, 16995, South Korea

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

CHRONIC CORONARY SYNDROME